Current stage-Stage III Posts on Medivizor
Navigation Menu

Current stage-Stage III Posts on Medivizor

Evaluating S-1 plus cisplatin with radiotherapy for inoperable stage III non-small cell lung cancer

Evaluating S-1 plus cisplatin with radiotherapy for inoperable stage III non-small cell lung cancer

Posted by on Feb 25, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at the use of chemotherapy with S-1 (Teysuno) plus cisplatin (Platinol) versus docetaxel (Taxotere) plus cisplatin and radiotherapy (RT) for stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed. The authors found that S-1 plus cisplatin (SP) should be considered as a treatment...

Read More

Can circulating tumor cells help in improving the outcomes of patients with breast cancer?

Can circulating tumor cells help in improving the outcomes of patients with breast cancer?

Posted by on Feb 6, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the role of circulating tumor cells (CTCs) in deciding adjuvant therapy (AT; treatment after surgery) in patients with breast cancer (BC). This study showed that personalized AT based on CTCs improved patient survival. Some background BC that has not spread to other areas of the body is called non-metastatic...

Read More

Looking for patients with HER-2 positive advanced breast cancer to trial an experimental treatment.

Looking for patients with HER-2 positive advanced breast cancer to trial an experimental treatment.

Posted by on Jan 28, 2021 in Breast cancer | 0 comments

In a nutshell This trial is aiming to examine the safety and effectiveness of an experimental treatment called BPX-063, a CAR-T cell treatment, in patients with advanced HER-2 positive breast cancer. The main outcomes to be measured are the maximum tolerated dose of BPX-603 and the antitumor activity. This trial is being carried out across the...

Read More

Bevacizumab combined with first-line chemotherapy for metastatic colorectal cancer in a real-world setting

Bevacizumab combined with first-line chemotherapy for metastatic colorectal cancer in a real-world setting

Posted by on Jan 19, 2021 in Colorectal cancer | 0 comments

In a nutshell This article looked at the effectiveness of bevacizumab (Avastin) with chemotherapy for metastatic colorectal cancer (mCRC) in a real-world setting. The authors found that the addition of bevacizumab to chemotherapy regimens provides survival benefits in patients who cannot undergo curative local treatment. Some background...

Read More

Evaluating erlotinib plus radiotherapy for stage 3, EGFR-positive non-small cell lung cancer that cannot be surgically removed

Evaluating erlotinib plus radiotherapy for stage 3, EGFR-positive non-small cell lung cancer that cannot be surgically removed

Posted by on Jan 17, 2021 in Lung cancer | 0 comments

In a nutshell This trial was carried to look at the use of erlotinib (Tarceva) with radiotherapy (RT) compared to standard treatment for EGFR-positive non-small cell lung cancer (NSCLC) that cannot be removed surgically. The authors found that erlotinib and RT improved survival without cancer worsening in these patients. Some...

Read More

Irinotecan combined with capecitabine-based chemoradiotherapy before surgery improves the outcomes of patients with rectal cancer

Irinotecan combined with capecitabine-based chemoradiotherapy before surgery improves the outcomes of patients with rectal cancer

Posted by on Nov 29, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of treatment with irinotecan (Camptosar) combined with capecitabine (Xeloda) chemotherapy (ICC) before rectal cancer surgery. Researchers suggested that this combined therapy significantly improved the treatment outcomes in these patients. Some background Rectal cancer is a common...

Read More

Searching for patients with non-small cell lung cancer to trial an immune treatment

Searching for patients with non-small cell lung cancer to trial an immune treatment

Posted by on Nov 22, 2020 in Lung cancer | 0 comments

In a nutshell This trial is being carried out to examine the effectiveness of a new immune therapy, zimberelimab, alone or in combination with other immune therapies (domvanalimab and etrumadenant) in patients with PD-L1 positive non-small cell lung cancer (NSCLC). The main outcomes to be measured in this trial is the response rate and survival...

Read More

Evaluating timing between chemoradiotherapy and surgery in patients with rectal cancer.

Evaluating timing between chemoradiotherapy and surgery in patients with rectal cancer.

Posted by on Nov 15, 2020 in Colorectal cancer | 0 comments

In a nutshell This trial was carried out to examine the optimal time interval between completing chemoradiotherapy (CRT) and robotic-assisted surgery (RAS) in patients with rectal cancer. The trial found that RAS is safe and effective after 10-12 weeks of CRT. Some background Rectal cancer treatment has experienced an improvement with new...

Read More

Predicting response to 10 years of endocrine therapy in patients with hormone receptor positive early stage breast cancer

Predicting response to 10 years of endocrine therapy in patients with hormone receptor positive early stage breast cancer

Posted by on Nov 15, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated whether Breast Cancer Index (BCI) can predict benefits from extended endocrine therapy (EET) in patients with hormone-receptor-positive (HR+) early-stage breast cancer (BC). The authors found that BCI can predict which patients would benefit from 10 years of EET. Some background Endocrine therapy (ET) prevents tumor...

Read More

Can tumor DNA in the blood predict how well patients with melanoma will respond to immune therapy?

Can tumor DNA in the blood predict how well patients with melanoma will respond to immune therapy?

Posted by on Nov 13, 2020 in Melanoma | 0 comments

In a nutshell This study looked at the role of circulating tumor DNA (ctDNA) in predicting treatment response in advanced melanoma. They found that in patients treated for the first time with immune treatment, patients with low ctDNA levels had a longer survival without cancer worsening. Some background Advanced melanoma describes melanoma...

Read More